Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 5/2020

25.03.2020 | Correction

Correction to: Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer

verfasst von: Hani M. Babiker, Mohammed Milhem, Joseph Aisner, William Edenfield, Dale Shepard, Michael Savona, Swaminathan Iyer, Maen Abdelrahim, C. L. Beach, Barry Skikne, Eric Laille, Kao-Tai Tsai, Thai Ho

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Excerpt

In the original publication of the article the author has found few incorrect values in the Table 1. The corrected Table 1 is given below.
Table 1
Food effect on the plasma pharmacokinetic parameters of the CC-486 300 mg Formulation B tablet
Condition
Statistic
AUCt (ng h/mL)
AUC (ng h/mL)
Cmax (ng/mL)
Tmax (h)
t1/2 (h)
CL/F (L/h)
Vz/F (L)
Fasted
N
56
54
56
56
54
54
54
Geometric Meana
224.9
234.5
131.7
NA
0.58
1280
1074
Geometric %CV
68.4
62.9
70.4
NA
31.6
62.9
76.2
Median
240
243
141
1.0
0.55
1230
1140
Min, max
41.5, 1050
65.9, 1050
21.4, 608
0.50, 4.0
0.35, 1.7
286, 4550
228, 6310
Fed
N
55
44
55
55
46
44
44
Geometric Meana
233.7
248.9
105.2
NA
0.78
1205
1279
Geometric %CV
58.3
52.0
76.3
NA
55.2
52.0
80.5
Median
250
250
116
2.0
0.68
1200
1160
Min, Max
61.3, 554
78.9, 560
22.7, 337
0.50, 6.1
0.40, 6.2
536, 3800
399, 9350
PK parameter
Condition
N
Geometric mean
Ratio (%) of geometric means
90% CI of ratio (%) of geometric means
Intra-patient %CV
AUCt (ng h/mL)
Fasted
56
227.8
101.7
(92.83, 111.5)
29.0
Fed
55
231.8
AUC (ng h/mL)
Fasted
54
237.5
108.9
(98.48, 120.5)
28.3
Fed
44
258.7
Cmax (ng/mL)
Fasted
56
133.0
78.86
(68.58, 90.68)
45.5
Fed
55
104.9
PK parameter
Condition
N
Median
Median difference
90% CI of median difference (Fed–fasted)
P value
Tmax (h)
Fasted
56
1.0
1.0
(0.75, 1.3)
 < 0.001
Fed
55
2.0
N patients = the total number of patients for which the PK parameter could be calculated. AUC, t1/2, CL/F, and V/F could not be calculated in some instances, if there were not data from a sufficient number of time points after the occurrence of Cmax
Slight differences in geometric means of AUC and Cmax are due to different methods of calculation
AUCt area under the plasma concentration–time curve from time 0 to time t, AUC area under the plasma concentration–time curve from time 0 extrapolated to infinity, Cmax maximum plasma concentration, Tmax time to Cmax, t1/2 terminal half-life, CL/F apparent total clearance, Vz/F volume of distribution, NA not applicable
Calculated using an analysis of variance (ANOVA) model
Median and median difference (Test vs. Reference), and 90% CI of the median difference, are from Hodges-Lehmann estimate. The P value is from Wilcoxon signed-rank test
aCalculated using summary statistics.
Metadaten
Titel
Correction to: Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer
verfasst von
Hani M. Babiker
Mohammed Milhem
Joseph Aisner
William Edenfield
Dale Shepard
Michael Savona
Swaminathan Iyer
Maen Abdelrahim
C. L. Beach
Barry Skikne
Eric Laille
Kao-Tai Tsai
Thai Ho
Publikationsdatum
25.03.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 5/2020
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-020-04056-6

Weitere Artikel der Ausgabe 5/2020

Cancer Chemotherapy and Pharmacology 5/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.